Cellular Immunotherapy of Cancer: The use of Lymphokine-Activated Natural Killer (LANAK) Cells-Reference-Cited by-同舟云学术

Cellular Immunotherapy of Cancer: The use of Lymphokine-Activated Natural Killer (LANAK) Cells

Published:1990 Issue: Volume: Page:47-56
ISSN:
Container-title:Lymphohaematopoietic Growth Factors in Cancer Therapy
language:
Short-container-title:

Author:

Farace Françoise,Escudier Bernard,Triebel Frédéric,Hercend Thierry

Publisher

Springer Berlin Heidelberg

Link

http://link.springer.com/content/pdf/10.1007/978-3-642-76037-2_6.pdf

Reference36 articles.

1. Oliver RTD: The clinical potential of InterleukJn-2. Br J Cancer 1988 (58):405–409.

2. Pinsky CM, Camacho FJ, Kerr D, Geller NL, Klein FA, Herr HA, Whitmore WF and Oettgen HF: Intravesical administration of Bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep 1985 (69):47–53.

3. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp C and White DE: Experience with the use of high-dose Interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989 (210):474–485.

4. Lotze MT, Grimm EA, Mazumder A, Strausser JL and Rosenberg SA: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981 (41):4420–4425.

5. Rosenberg S: Lymphokine-activated killer cells: A new approach to immunotherapy of cancer. JNCI 1985 (75):595–603.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lymphohaematopoietic Growth Factor Use in Lung Cancer Patients;Lymphohaematopoietic Growth Factors in Cancer Therapy II;1992